Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Molecular markers associated with lymph node metastasis in pancreatic ductal adenocarcinoma by genome-wide expression profiling
Cancer Science, 10/28/09

Hirono S et al. –Lymph node metastasis (LNM) is the most important prognostic factor in patients undergoing surgical resection of pancreatic ductal adenocarcinoma (PDAC). AP2 &alpha and MUC17 were independent markers associated with LNM of PDAC. These two markers were also associated with survival in patients with resected PDAC. We demonstrate that AP2? and MUC17 may serve as potential prognostic molecular markers for LNM in patients with PDAC.

Methods

Laser microdissection and genome-wide transcriptional profiling used to identify genes that were differentially expressed between PDAC cells with and without LNM obtained from 20 patients with PDAC
Immunohistochemical staining was used to confirm the clinical significance of these markers in additional validation set of 43 patients

Results

Microarray profiling identified 46 genes that were differently expressed between PDAC with and without LNM with certain significance
4 of these biomarkers validated by immunohistochemical staining for association with LNM in PDAC in additional validation set of patients
In 63 patients with PDAC, significant LNM predictors in PDAC elucidated from multivariate analysis were low expression of activating enhancer binding protein 2 (AP2 &alpha) and high expression of mucin 17 (MUC17)
Multivariate analysis revealed that AP2 &alpha-low expression and MUC17-high expression are independent prognostic factors for poor overall survival (P = 0.0012, 0.0001, respectively)

<< Previous
Nuclear factor-kappa B pathway and response in a phase II trial...

Next >>
A phase II, multicenter study of cetuximab monotherapy in...